52. SPACs and infectious disease past and future, Joe Hernandez, CEO, Blue Water Acquisition Corp.
Joseph Hernandez is an established leader in biotech entrepreneurship and early-stage technology development. With a strong background in biology, epidemiology, molecular genetics, marketing, and fina...
31 Mar 202122min
51. Pioneering innovations for neurological indications, Chris Wright, CMO, Cyclerion
Chief Medical Officer, Christopher Wright, MD, PhD, is a neurologist and neuroscientist who brings two decades of medical research and drug development experience in orphan and specialty diseases, inc...
25 Mar 202127min
50. Noninvasive diagnostics for NASH and inflammatory indications, Caroline Loew, CEO, Glympse Bio
Caroline is a biopharmaceutical executive with over 20 years of experience successfully leading diverse, empowered, and integrated teams. She has broad experience integrating science, business, and th...
17 Mar 202127min
49. Restoring connections for neurodegenerative diseases, Leen Kawas, CEO, Athira Pharma
Leen Kawas, Ph.D., has served as our chief executive officer and as a member of our board of directors since January 2014. Previously, Dr. Kawas served as our vice president. Dr. Kawas serves on multi...
10 Mar 202118min
48. Anti-TNF: From Arthritis to Dementia and Fibrosis, Jim Woody, CEO, 180 Life Sciences
Jim Woody has more than 25 years of pharmaceutical research and management expertise He currently serves as Chairman of Oncomed Pharmaceuticals, where he was previously a founder and CEO; he is also ...
3 Mar 202122min
47. Next generation cell-free cancer and autoimmune therapeutics, Bill Newell, CEO, Sutro Biopharma
William J. Newell has served as our Chief Executive Officer and a member of our Board of Directors since January 2009. Previously, he served as the President of Aerovance, Inc., a biotechnology compan...
24 Feb 202131min
46. Fighting cancer with protein degradation, Adam Crystal, CMO, Stew Fisher, CSO, C4 Therapeutics
Adam Crystal, M.D., Ph.D. joined C4 Therapeutics in February 2019 as our Chief Medical Officer. Previously, Adam was at Novartis Institutes for Biomedical Research, most recently as Senior Director, w...
17 Feb 202133min
45. Next generation of cell therapy, Brian Culley, CEO, Lineage Cell Therapeutics
Mr. Culley joined Lineage as Chief Executive Officer in September 2018. Prior to joining Lineage, Mr. Culley served from August 2017 to September 2018 as interim Chief Executive Officer at Artemis The...
10 Feb 202127min
